SCHEMBL2180657

SCHEMBL2180657

COC(=O)CCCN1Cc2ccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.49
DGAT1 O75907 4/20 0.48
PDGFRB P09619 3/20 0.47
LCK P06239 3/20 0.44
FYN P06241 3/20 0.44
CSF1R P07333 3/20 0.44
LYN P07948 3/20 0.44
KIT P10721 3/20 0.44
FLT1 P17948 3/20 0.44
FLT4 P35916 3/20 0.44
BLK P51451 3/20 0.44
MAPT P10636 3/20 0.44
NTRK1 P04629 3/20 0.44
NTRK2 Q16620 3/20 0.44
AURKB Q96GD4 3/20 0.44
SRC P12931 2/20 0.44
FLT3 P36888 2/20 0.44
ROCK2 O75116 2/20 0.44
EGFR P00533 2/20 0.44
EPHA2 P29317 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181303 0.93 DGAT1 (0.52) KDRDGAT1PDGFRBLCKFYN
SCHEMBL2180560 0.91 DGAT1 (0.52) KDRDGAT1PDGFRBLCKFYN
SCHEMBL2180896 0.90 KDR (0.52) KDRDGAT1PDGFRBLCKFYN
SCHEMBL27894572 0.89 KDR (0.52) KDRDGAT1PDGFRBLCKFYN
SCHEMBL2178394 0.84 DGAT1 (0.56) KDRDGAT1PDGFRBLCKFYN
SCHEMBL2177703 0.83 DGAT1 (0.55) KDRDGAT1PDGFRBLCKFYN
SCHEMBL2179512 0.83 DGAT1 (0.55) KDRDGAT1PDGFRBLCKFYN
SCHEMBL27894559 0.82 DGAT1 (0.55) KDRDGAT1PDGFRBLCKFYN
SCHEMBL27877708 0.82 DGAT1 (0.52) KDRDGAT1PDGFRBLCKFYN
SCHEMBL2180194 0.81 DGAT1 (0.56) KDRDGAT1LCKFYNCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT KDR 4082/4885DGAT1 1/4885PDGFRB 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.